Editor's Note: From December 9 to 12, the highly anticipated 65th American Society of Hematology (ASH) Annual Meeting took place in San Diego, USA. Focused on the annual pinnacle in the field of hematologic malignancies, the front-line reporting team of "Oncology Insights" delved into the forefront, witnessing the outstanding performance of "China's Good Voice" on the international stage. In the realm of aggressive lymphomas, advancements in targeted and cellular immunotherapy continue to dominate. To comprehensively grasp the lymphoma treatment developments at this ASH conference, "Oncology Insights" had the privilege of interviewing Professor Lin Tongyu from Sun Yat-sen University Cancer Hospital, who provided insightful analysis on the topic.
Prof. Lin Tongyu Commemorates Advances in Lymphoma Field at ASH Conference
At the ASH conference, Professor Lin Tongyu provided an overview of the progress in the field of lymphoma, with a focus on targeted therapies, immunotherapy, and CAR-T treatments. In B-cell lymphomas, exploration of targets remains a key theme. This year, the LBA-2 study demonstrated that combining the BTK inhibitor Ibrutinib with the Bcl-2 inhibitor Venetoclax improves outcomes in refractory/relapsed mantle cell lymphoma (R/R-MCL). The diagnosis and treatment of MCL have evolved significantly, initially considered an indolent lymphoma until Professor at MD Anderson Cancer Center first proposed it as an aggressive lymphoma in 1996. Treatment has progressed through three stages, with early radiation therapy being crucial, and the introduction of Rituximab enhancing efficacy in immunotherapy regimens like CHOP/DHAP. Additionally, high-dose cytarabine (Ara-C) combined with autologous stem cell transplantation offers a potential cure for young and transplant-eligible MCL patients, although some still progress to refractory/relapsed stages.
In diffuse large B-cell lymphoma (DLBCL), a noteworthy study (abstract 434) employed the ViPOR regimen (Venetoclax + Ibrutinib + Obinutuzumab + lenalidomide + prednisone) to treat refractory/relapsed DLBCL patients, achieving promising results. Targeting CD20/CD3 bispecific antibodies also proved to be a favorable option for R/R-DLBCL treatment. CAR-T therapy remains a crucial treatment option for high-risk, elderly, or DLBCL patients unsuitable for standard chemotherapy. Studies presented at this year’s ASH conference demonstrated the efficacy of CD19/CD22 dual-target CAR-T in DLBCL treatment.
In the treatment of T-cell lymphomas, research revealed that PD-1 monoclonal antibodies combined with CD38 monoclonal antibodies demonstrated significant efficacy in refractory/relapsed NK/T-cell lymphoma. Regarding peripheral T-cell lymphoma (PTCL) treatment, our team’s study (abstract 304) was selected for an oral presentation. The use of EZH1/2 inhibitors such as HH2853 in refractory/relapsed PTCL (R/R-PTCL) showed a remarkable overall response rate (ORR) of 60.7%, with a complete response (CR) rate of 21.4%. This represents the first clinical study in this field in China, with positive results, and ongoing phase II studies in Japan and other countries aim to bring further advancements in the future.
Professor Lin Tongyu
Dean of the Affiliated Cancer Hospital of the School of Medicine, University of Electronic Science and Technology of China · Sichuan Cancer Hospital
Professor, Chief Physician, Ph.D. Supervisor, Chief Expert
Professor, Chief Physician, Ph.D. Supervisor, Chief Expert
Cancer Prevention and Treatment Center, Sun Yat-sen University
Deputy Director of the Oncology Department of the Chinese Medical Association
Chairman of the Lymphoma Group of the Oncology Branch of the Chinese Medical Association
Chairman of the Rare Tumors Expert Committee of the Chinese Society of Clinical Oncology (CSCO)
Deputy Chairman of the Melanoma Expert Committee of CSCO
Vice Chairman of the Chinese Lymphoma Alliance of CSCO
Deputy Chairman of the Expert Committee on Anticancer Drug Safety Management in China
Chairman of the South China Clinical Oncology Research Association (CSWOG)
Expert Reviewer for the National Natural Science Foundation, Expert of the National Expert Committee on Rational Drug Use, and Expert of the National Expert Committee on Medical Accidents
Healthcare Expert for Central and Provincial Governments
Vice President of the Sichuan Medical Association
Chairman of the Oncology Branch of the Guangdong Medical Association
